GRAIL, Inc. (GRAL)
NASDAQ: GRAL · Real-Time Price · USD
100.98
-3.73 (-3.56%)
At close: Dec 5, 2025, 4:00 PM EST
100.18
-0.80 (-0.79%)
After-hours: Dec 5, 2025, 7:50 PM EST

Company Description

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally.

It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.

The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development.

In addition, it develops minimal residual disease post-diagnostic tests. The company was incorporated in 2015 and is headquartered in Menlo Park, California.

GRAIL, Inc.
GRAIL logo
Country United States
Founded 2016
Industry Diagnostics & Research
Sector Healthcare
Employees 1,000
CEO Robert Ragusa

Contact Details

Address:
1525 O’Brien Drive
Menlo Park, California 94025
United States
Phone 833 694 2553
Website grail.com

Stock Details

Ticker Symbol GRAL
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001699031
CUSIP Number 384747101
ISIN Number US3847471014
Employer ID 86-3673636
SIC Code 8071

Key Executives

Name Position
Robert P. Ragusa Chief Executive Officer and Director
Dr. Joshua J. Ofman M.D., M.S.H.S President
Aaron Freidin Chief Financial Officer
Paul Ciccolella Senior Vice President of Global Development and Operations
Abram Barth J.D., M.P.H. General Counsel
Alexis Tosti Vice President of Strategy and Corporate Development
Alison Highlander Senior Vice President of Human Resources and Head of People Team
Dr. Satnam Alag Ph.D. Senior Vice President of Software Engineering and Chief Security Officer
Andrew John Partridge Chief Commercial Officer
Dr. Eric T. Fung M.D., Ph.D. Senior Vice President of Clinical Development

Latest SEC Filings

Date Type Title
Dec 3, 2025 144 Filing
Dec 3, 2025 144 Filing
Dec 3, 2025 144 Filing
Nov 24, 2025 SCHEDULE 13G Filing
Nov 14, 2025 144 Filing
Nov 14, 2025 8-K Current Report
Nov 14, 2025 424B5 Filing
Nov 13, 2025 424B7 Filing
Nov 13, 2025 S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
Nov 13, 2025 10-Q Quarterly Report